Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (161-170 of 188) with videos related to

Pageof 19
Sort By:
Blood|March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease ResultsJill Corre, Laure Vincent, Philippe Moreau, et al.
Blood|May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaMeletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
Leukemia|August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Advances in Therapy|December 19, 2023
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple MyelomaPhilippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia, et al.
Cancers|September 9, 2023
Outcome of Second Primary Malignancies Developing in Multiple Myeloma PatientsIrit Avivi, David H Vesole, Julio Davila-Valls, et al.
Haematologica|January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHenk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
Leukemia & Lymphoma|July 3, 2018
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patientsArtur Jurczyszyn, Jorge J Castillo, Irit Avivi, et al.
Leukemia|May 4, 2018
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Michel Delforge, Thierry Facon, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
British Journal of Haematology|January 10, 2018
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patientsArtur Jurczyszyn, Jakub Radocha, Julio Davila, et al.
Pageof 19

Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
Blood|March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease ResultsJill Corre, Laure Vincent, Philippe Moreau, et al.
Blood|May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaMeletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
Leukemia|August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Advances in Therapy|December 19, 2023
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple MyelomaPhilippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia, et al.
Cancers|September 9, 2023
Outcome of Second Primary Malignancies Developing in Multiple Myeloma PatientsIrit Avivi, David H Vesole, Julio Davila-Valls, et al.
Haematologica|January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHenk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
Leukemia & Lymphoma|July 3, 2018
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patientsArtur Jurczyszyn, Jorge J Castillo, Irit Avivi, et al.
Leukemia|May 4, 2018
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Michel Delforge, Thierry Facon, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
British Journal of Haematology|January 10, 2018
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patientsArtur Jurczyszyn, Jakub Radocha, Julio Davila, et al.
Pageof 19